A phase 1/2 trial of 7MW4911 in advanced solid tumours, run by Mabwell (Shanghai) Bioscience Co., Ltd., now recruiting.
First-in-human Study of 7MW4911 in GI Cancer is a phase 1/2 interventional study registered as NCT07216560 by Mabwell (Shanghai) Bioscience Co., Ltd., with 200 participants planned, started 2026-01-13 and due to reach its primary completion in 2027-07. Interventions recorded: 7MW4911.
Shares Mabwell (Shanghai) Bioscience, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Mabwell (Shanghai) Bioscience, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Mabwell (Shanghai) Bioscience, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Mabwell (Shanghai) Bioscience and the tag pipeline.
Shares Mabwell (Shanghai) Bioscience and the tag pipeline.
Shares Mabwell (Shanghai) Bioscience and the tag pipeline.
Shares Mabwell (Shanghai) Bioscience and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.